RecruitingPhase 4NCT06057402

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

ELRANATAMAB POST TRIAL ACCESS: AN OPEN-LABEL, SINGLE-ARM STUDY FOR PARTICIPANTS WITH MULTIPLE MYELOMA CONTINUING FROM PFIZER-SPONSORED ELRANATAMAB CLINICAL STUDIES

Sponsor

Pfizer

Enrollment

80 participants

Start Date

Oct 3, 2023

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma

Summary

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a post-trial access study that allows patients who were in a previous clinical trial of elranatamab (a bispecific antibody treatment for multiple myeloma) and are still benefiting from it to continue receiving the drug after their original trial ended. **You may be eligible if...** - You previously participated in a qualifying elranatamab parent study - You were still receiving elranatamab when that study ended - Your doctor has determined you are still clinically benefiting from the treatment - You meet contraception requirements as outlined in the protocol **You may NOT be eligible if...** - You have not previously participated in a qualifying elranatamab parent study - You stopped treatment in a prior study for any reason - You have a serious psychiatric condition including recent active suicidal ideation - You have laboratory or medical abnormalities that significantly increase the risk of participation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGElranatamab

Elranatamab is a heterodimeric humanized full-length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells

Locations(28)

UCHealth Poudre Valley Hospital

Fort Collins, Colorado, United States

UCHealth Harmony

Fort Collins, Colorado, United States

UCHealth Greeley Hospital

Greeley, Colorado, United States

Longs Peak Hospital

Longmont, Colorado, United States

UCHealth Longs Peak Medical Center

Longmont, Colorado, United States

UCHealth - Medical Center of the Rockies

Loveland, Colorado, United States

Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center

Coral Gables, Florida, United States

University of Miami Hospital and Clinics Deerfield Beach

Deerfield Beach, Florida, United States

Sylvester Comprehensive Cancer Center

Miami, Florida, United States

University of Miami Hospital and Clinics - Griffin Cancer Research Building

Miami, Florida, United States

University of Miami Hospital and Clinics

Miami, Florida, United States

University of Michigan

Ann Arbor, Michigan, United States

Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)

Detroit, Michigan, United States

St. David's South Austin Medical Center

Austin, Texas, United States

Epworth Freemasons

Melbourne, Victoria, Australia

Epworth Hospital

Richmond, Victoria, Australia

Slade Pharmacy

Richmond, Victoria, Australia

Arthur J.E. Child Comprehensive Cancer Centre

Calgary, Alberta, Canada

Cross Cancer Institute

Edmonton, Alberta, Canada

McGill University Health Centre

Montreal, Quebec, Canada

Peking University Third Hospital

Beijing, Beijing Municipality, China

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Shandong Provincial Hospital

Jinan, Shandong, China

The first Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Japanese Red Cross Medical Center

Shibuya-ku, Tokyo, Japan

University Hospital,Kyoto Prefectural University of Medicine

Kyoto, Japan

National Taiwan University Hospital

Taipei, Taiwan

Taipei Veterans General Hospital

Taipei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06057402

Related Trials

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

NCT0558361716 locations

Tissue Collection for Studies of Lymph Cancer

NCT016768052 locations

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

NCT0617988874 locations

18F-Fluciclovine PET/CT in Multiple Myeloma

NCT061038381 location

PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.

NCT059471361 location